Status:
COMPLETED
Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
Lead Sponsor:
Abbott
Collaborating Sponsors:
Eisai Limited
Conditions:
Psoriasis
Eligibility:
All Genders
20+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of the study is to assess the efficacy and safety of repeated administration of adalimumab in adult Japanese subjects with moderate to severe chronic plaque psoriasis.
Eligibility Criteria
Inclusion
- Subject was age 20 or older and in good health (Investigator discretion) with a recent stable medical history.
- Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis
Exclusion
- Subject had previously received anti-TNF therapy.
- Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVA, UVB or PUVA phototherapy
- Subject is taking or requires oral or injectable corticosteroids
- Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
- Female subject who is pregnant or breast-feeding or considering becoming pregnant
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00338754
Start Date
November 1 2005
Last Update
September 11 2007
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Chugoku, Japan
2
Chūbu, Japan
3
Hokkaido, Japan
4
Kanto, Japan